ORKA

$79.92

+1.05% Oct 21 close

Sector n/a Compare

1M 3M 6M 1Y 2Y

ORKASPY

+4.2%

-14.4%

-13.6%

+14.7%

YTD

+163.7%

+192.1%

Live chart

Loading live chart…

What they do

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO.

Healthcare · Biotechnology

For information only · Important disclosures

Grades vs sector

No sector grades for ORKA yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Our models

Not held by any of our 5 live models right now.

Quality Growth

Outside this model's universe or screens

Momentum Top 15

Outside this model's universe or screens

Momentum Blend

Not in the current book

New Highs Growth

Outside this model's universe or screens

Coteau Long Book

Not in the current book

News

More news

No recent headlines.

Key stats

52-week range$26.19 – $113.08

Valuation and fundamentals

Valuation & fundamentals

Bottom line

No cash-flow valuation

Model read-out from the numbers below, not advice. Score -1 (DCF counts double).

▼Piotroski F-score3/9

Discounted cash flow

Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.

Reverse DCFfor context, not a signal

Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2024-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs sector

Quality & financial health

Gross margin

–

Operating margin

–

FCF margin

–

Net margin

–

Return on equity

-11.9%

Return on invested capital

-50.8%

Net debt / EBITDA

–

Current ratio

38.5×

Interest cover

–

Cash conversion (OCF/NI)

–

Piotroski F-score 3/9 · last two fiscal years

✗ Positive net income✗ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✓ No share dilution✗ Gross margin improved✗ Asset turnover improved

Analysts

No analyst targets available.

Annual history

FY	Revenue	Net income	Free cash flow
2023	$0	$-5.3M	$-5.0M
2022	$0	$-9.9M	$-10.9M
2021	$0	$-19.3M	$-18.8M
2020	$0	$-9.7M	$-7.7M
2019	$0	$-5.5M	$-4.8M
2018	$0	–	–

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.

Earnings

Next report: 2026-11-11 · before open · EPS est -0.62

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-08-10	-0.50	-0.55	-9.9%
2026-05-13	-0.54	-0.48	+10.6%
2026-03-12	-0.62	-0.45	+26.9%
2025-11-12	-0.52	-0.55	-5.0%
2025-08-11	-0.43	-0.46	-6.4%
2025-05-14	-0.44	-0.40	+9.1%
2025-03-06	-0.41	-0.49	-18.6%
2024-11-13	-0.32	-1.46	-351.6%

Insider trades

Quinlan Paul T

General Counsel · 2026-10-20

Sell
$238.5K

Quinlan Paul T

General Counsel · 2026-10-20

Sell
$323.0K

Quinlan Paul T

General Counsel · 2026-10-20

Sell
$77.2K

Quinlan Paul T

General Counsel · 2026-10-20

Sell
$38.1K

Quinlan Paul T

General Counsel · 2026-10-20

Sell
$30.0K

Goncalves Joana